INC Research has appointed Robert Ryan as vice president of regulatory strategy, consulting and submissions within its new Strategic Advisory Services unit.
He joins the contract research organisation (CRO) from CNS and pain-focused pharmaceutical development company Levare, where he was chairman of the board.
Prior to this Ryan spent time with other CROs and biopharmaceutical companies, including Quintiles, PPD, Celtic Therapeutics and Schwarz Pharma.
In his new role at INC Ryan will be tasked with positioning INC’s new Strategic Advisory Services as a market leader in regulatory consulting and submissions offerings.
Tim Dietlin, senior vice president of global consulting and strategic alliances, said: “Robert brings a unique blend of strategic leadership skills and international regulatory expertise that speaks to biopharmaceutical companies looking for guidance along the entire continuum of the drug development life cycle.
“Our Regulatory Consulting and Submissions team has a long history of exceptional work, and we look forward to continuing this track record under Robert’s leadership.”